Fake Rabies Vaccine Sparks Urgent Health Probe in India

Indian health authorities are racing against time to uncover the source of potentially dangerous counterfeit rabies vaccines that failed critical quality tests. The discovery has sent shockwaves through the medical community, raising urgent questions about patient safety and pharmaceutical supply chain integrity.

How the counterfeit operation unraveled

The alarm bells rang when officials from Delhi's Drugs Control Department and police seized suspicious vaccine samples during a raid on an unlicensed residential property. What they found sent chills through the regulatory community—vials that looked like legitimate rabies vaccines but showed 17 distinct differences from genuine products upon closer inspection.

From packaging discrepancies to altered QR codes and wrong cap colors, the counterfeit operation showed disturbing sophistication. The Central Drugs Laboratory in Kasauli confirmed the worst: the vaccines lacked proper potency and were officially declared "not of standard quality."

Manufacturer's swift response

Indian Immunologicals Ltd., which produces the authentic Abhayrab vaccine, moved quickly to distance itself from the scandal. In a September 4 statement, the company revealed that their genuine KE25012 batch—83,370 vials released in November 2025—underwent proper testing and distributed through authorized channels.

"Importantly, the laboratory identified 17 differences between the questioned vials and the genuine retention samples," the company stated, clearly indicating counterfeiters had hijacked their batch number.

The manufacturer has fully cooperated with investigators, submitting comprehensive manufacturing and distribution records to help trace the fake products' origin.

Public health implications

This case carries particularly grave weight because rabies proves almost universally fatal once symptoms appear. Effective vaccination after exposure becomes a matter of life and death—making counterfeit vaccines potentially lethal.

While authorities haven't confirmed whether any patients received the fake doses, the Drugs Controller General of India has alerted all state regulators to monitor movement of the suspect batch. Thankfully, no part of this batch was exported internationally.

This marks the second counterfeit scare involving Abhayrab in recent years, following a similar incident with batch KA24014 in 2025 that prompted health warnings for travelers to India.